Advances In™ Marginal Zone Lymphoma: Applying New Developments to Practice

Release Date: December 22, 2021
Expiration Date: December 22, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from BeiGene, Ltd., and TG Therapeutics, Inc.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the pathogenesis of different subtypes of marginal zone lymphoma (MZL), and assess how this informs decision making for patients with this malignancy
• Assess recent evidence on the use of targeted and immunotherapeutic approaches for the treatment of patients with MZL
• Describe the impact of emerging data as well as strategies in the context of evolving treatment paradigms in the management of patients with MZL
• Identify patients with MZL who may benefit from clinical trial participation evaluating emerging therapies and/or strategies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
 

Faculty

Sameh Gaballa, MD
Assistant Member
Department of Malignant Hematology
Moffitt Cancer Center
Assistant Professor
Department of Oncologic Sciences
Morsani College of Medicine
University of South Florida
Tampa, Florida

Disclosures: Grant/Research Support: Epizyme, Adaptive Biotechnologies. Consultant: AbbVie. Speaker’s Bureau: TG Therapeutics, ADC Therapeutics. Advisory Board: Epizyme, BeiGene, TG Therapeutics, ADC Therapeutics.

 

Felipe Samaniego, MD
Professor of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

 

Disclosures:  Consultant: Imbrium Therapeutics, TG Therapeutics.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
 

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.